The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Founder and CEO George Kurtz made a compelling argument that we agree with, so why can't the rest of the market get behind him?

Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

Once used by vets to anesthetize elephants, carfentanil is now an extremely dangerous illicit drug often disguised as an ...

If it sounds like Dr. MacBride is describing intelligence, it's because she is. Indeed, some "frustrating" behaviors can ...

For National Consumer Protection Week, NAEBA calls for transparency, accurate sales data, and Fair Housing compliance ...

Packaging continues to be a stable and growing industry, with plenty of opportunities for commercial printers to get in on the action. Here’s what 2026 has in store for this segment.

This situation is a great reminder of advice a good friend shared with me years ago: Every difficult moment is a gift. The challenge—for leaders, especially— is developing the discipline to find that ...

The humble gherkin ties Indian farms to a global pickle trade of $200 million. As buyers look beyond the US market, the tiny ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...

If you only have time to track a few Tech Trends this year, focus on the ones that change cost, speed, and risk in real work.

The current kidney care model—focused on late-stage disease and in-center hemodialysis—is unsustainable, because of costs, environmental burden, poor outcomes, and reduced quality of life.